[Tafluprost--a novel prostaglandin F2alpha analogue].
The review provides a brief history of the evolution of ophthalmic containers: from glass vials to plastic bottles with obligatory preservatives and, finally, to preservative-free polypropylene single-use single-dose tubes. A brief characteristic of benzalkonium chloride, the most commonly used preservative, including mechanisms of its antiseptic activity and ocular toxicity is given. The problem of ocular surface damage, especially in glaucoma patients, due to the long-term use of preserved eye drops, is discussed. Pharmacodynamics of tafluprost, the first commercially available preservative-free single-dose prostaglandin analogue, is described. Operating characteristics of experimental preclinical studies and the first three phases of clinical trials of tafluprost are provided. Post-approval studies of the comparative efficacy and tolerability of the new drug are analyzed and its prospects for clinical use are assessed.